IOVANCE BIOTHERAPEUTICS Files 8-K on Security Holder Vote

TL;DR

IOVA filed an 8-K for a shareholder vote - big decisions ahead.

AI Summary

On June 11, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, formerly known as Lion Biotechnologies, Inc., is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing signals that important decisions requiring shareholder approval are being presented, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: low — The filing is a routine procedural report regarding a vote of security holders and does not disclose any immediate financial distress or significant negative events.

Key Players & Entities

• IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
• June 11, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Lion Biotechnologies, Inc. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke

Filing Documents

• tm2416997d1_8k.htm (8-K) — 39KB
• 0001104659-24-070470.txt ( ) — 210KB
• iova-20240611.xsd (EX-101.SCH) — 3KB
• iova-20240611_lab.xml (EX-101.LAB) — 33KB
• iova-20240611_pre.xml (EX-101.PRE) — 22KB
• tm2416997d1_8k_htm.xml (XML) — 4KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. Annual Meeting of Stockholders On June 11, 2024, the Iovance Biotherapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") virtually, via live webcast. At the Annual Meeting, the Company's stockholders voted on five proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 29, 2024. At the Annual Meeting, 225,242,787 shares, or approximately 80.492% of all shares of the Company's common stock outstanding as of the record date, were present either in person or by proxy. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter: Proposal 1 : a proposal to elect Iain Dukes, D. Phil., Athena Countouriotis, M.D., Ryan Maynard, Wayne P. Rothbaum, Frederick G. Vogt, Ph.D., J.D., Michael Weiser, M.D., Ph.D. and Wendy Yarno to the Board of Directors (the "Board") to serve as directors until the Company's 2024 Annual Meeting of Stockholders; Proposal 2 : a proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; Proposal 3 : a proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; Proposal 4 : a proposal to approve an amendment to the 2018 Equity Incentive Plan to increase the number of shares available for grant from 29,700,000 shares to 36,700,000 shares and permit share recapture from the 2014 Equity Incentive Plan; and Proposal 5 : a proposal to approve an amendment to the 2020 Iovance Employee Stock Purchase Plan to increase the number of shares available for grant from 1,400,000 shares to

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 11, 2024 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR